SPP1 and neoplasm: further demonstrated that targeting the SPP1-CD44 axis restored T-cell function and enhanced anti-PD-1 therapy efficacy in vitro, significantly reducing tumor burden (91), suggesting that SPP1-CD44 may be a promising therapeutic target to enhance antitumor immunity.